Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Analysts

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) have been assigned an average recommendation of "Hold" from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $3.67.

LXRX has been the subject of a number of research analyst reports. StockNews.com started coverage on Lexicon Pharmaceuticals in a report on Saturday. They set a "sell" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th. Leerink Partners reissued a "market perform" rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Finally, Piper Sandler lowered their price target on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th.

Remove Ads

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.42. 10,928,259 shares of the company's stock traded hands, compared to its average volume of 6,144,016. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The firm has a 50 day simple moving average of $0.57 and a two-hundred day simple moving average of $0.96. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.45. The stock has a market cap of $103.15 million, a price-to-earnings ratio of -0.56 and a beta of 1.04.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The company had revenue of $26.55 million during the quarter, compared to analysts' expectations of $6.48 million. On average, research analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Large investors have recently modified their holdings of the stock. California State Teachers Retirement System lifted its position in Lexicon Pharmaceuticals by 29.9% during the fourth quarter. California State Teachers Retirement System now owns 195,215 shares of the biopharmaceutical company's stock worth $144,000 after purchasing an additional 44,915 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Lexicon Pharmaceuticals by 193.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 353,508 shares of the biopharmaceutical company's stock valued at $261,000 after buying an additional 233,121 shares in the last quarter. Tang Capital Management LLC raised its position in shares of Lexicon Pharmaceuticals by 750.3% in the 4th quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company's stock valued at $628,000 after buying an additional 750,268 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Lexicon Pharmaceuticals by 630.7% during the 4th quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company's stock worth $6,638,000 after acquiring an additional 7,758,371 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Lexicon Pharmaceuticals by 378.0% during the 4th quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company's stock worth $234,000 after acquiring an additional 249,616 shares in the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.